Menu
Search
|

Menu

Close
X

Acer Therapeutics Inc ACER.OQ (NASDAQ Stock Exchange Capital Market)

18.16 USD
-- (--)
As of Feb 22
chart
Previous Close 18.16
Open --
Volume --
3m Avg Volume 5,963
Today’s High --
Today’s Low --
52 Week High 21.71
52 Week Low 5.70
Shares Outstanding (mil) 7.37
Market Capitalization (mil) 133.77
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
2
FY15
3
EPS (USD)
FY17
-2.719
FY16
-11.824
FY15
-23.521
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.75
Price to Sales (TTM)
vs sector
184.19
8.23
Price to Book (MRQ)
vs sector
7.93
5.26
Price to Cash Flow (TTM)
vs sector
--
26.16
Total Debt to Equity (MRQ)
vs sector
0.00
15.44
LT Debt to Equity (MRQ)
vs sector
0.00
12.05
Return on Investment (TTM)
vs sector
-122.46
13.63
Return on Equity (TTM)
vs sector
-122.46
15.25

EXECUTIVE LEADERSHIP

Christopher Schelling
President, Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
Harry Palmin
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Jason Kneeland
Vice President - Finance, Controller, Since 2017
Salary: --
Bonus: --
Terrie Kellmeyer
Vice President - Clinical Science, Since 2017
Salary: --
Bonus: --
John Klopp
Vice President - Manufacturing, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

One Gateway Center (300 Washingt
Suite 351
NEWTON   MA   02458

Phone: +1281.2729331

Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).

SPONSORED STORIES